Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 753-760

  Saliques, Sebastien ^a   Teyssier, Jean Raymond ^a,b   Vergely, Catherine ^a   Lorgis, Luc ^a,b   Lorin, Julie ^a   Farnier, Michel ^c   Donzel, Anne ^b   Sicard, Pierre ^a   Berchoud, Juliane ^b   Lagrost, Anne Cécile ^b   Touzery, Claude ^b   Ragot, Sylviane ^b   Cottin, Yves ^a,b   Rochette, Luc ^a   Zeller, Marianne ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c Le Point Médical   (France)

Author keywords

Leukocyte telomere length; Oxidative stress; Statin

Indexed keywords

8 OXOGUANINE DNA GLYCOSYLASE; ATORVASTATIN; DNA; DNA GLYCOSYLTRANSFERASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE FINKEL BISKIS JINKINS OSTEOSARCOMA; MESSENGER RNA; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE TELOMERE LENGTH; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DNA GLYCOSYLASES; DYSLIPIDEMIAS; FEMALE; GENETIC MARKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PROPENSITY SCORE; PROTO-ONCOGENE PROTEINS C-FOS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TELOMERE;

EID: 82955167885     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.011     Document Type: Article

References (34)

1. Benetos A., Gardner J.P., Zureik M., et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004, 43:182-185.
2. Valdes A.M., Andrew T., Gardner J.P., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366:662-664.
3. Gardner J.P., Li S., Srinivasan S.R., et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005, 111:2171-2177.
4. Panayiotou A.G., Nicolaides A.N., Griffin M., et al. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis 2010, 211:176-181.
5. Ogami M., Ikura Y., Ohsawa M., et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol 2004, 24:546-550.
6. Samani N.J., Boultby R., Butler R., et al. Telomere shortening in atherosclerosis. Lancet 2001, 358:472-473.
7. Fuster J.J., Andres V. Telomere biology and cardiovascular disease. Circ Res 2006, 99:1167-1180.
8. Brouilette S., Singh R.K., Thompson J.R., et al. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23:842-846.
9. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369:107-114.
10. Salpea K.D., Humphries S.E. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010, 209:35-38.
11. Babizhayev M.A., Savel'yeva E.L., Moskvina S.N., et al. Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther 2010.
12. Houben J.M., Moonen H.J., van Schooten F.J., et al. Telomere length assessment: biomarker of chronic oxidative stress?. Free Radic Biol Med 2008, 44:235-246.
13. Kawanishi S., Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann N Y Acad Sci 2004, 1019:278-284.
14. Lu J., Liu Y. Deletion of Ogg1 DNA glycosylase results in telomere base damage and length alteration in yeast. EMBO J 2010, 29:398-409.
15. Wang Z., Rhee D.B., Lu J., et al. Characterization of oxidative Guanine damage and repair in mammalian telomeres. PLoS Genet 2010, 6:e1000951.
16. Patino W.D., Mian O.Y., Kang J.G., et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci USA 2005, 102:3423-3428.
17. Spyridopoulos I., Haendeler J., Urbich C., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004, 110:3136-3142.
18. Assmus B., Urbich C., Aicher A., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049-1055.
19. Satoh M., Minami Y., Takahashi Y., et al. Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clin Sci (Lond) 2009, 116:827-835.
20. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002, 30:e47.
21. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
22. Heinze G., Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011, 32:1704-1708.
23. Thavendiranathan P., Bagai A., Brookhart M.A., et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307-2313.
24. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
25. Mahmoudi M., Gorenne I., Mercer J., et al. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ Res 2008, 103:717-725.
26. Willeit P., Willeit J., Brandstatter A., et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2010, 30:1649-1656.
27. Chen W., Kimura M., Kim S., et al. Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule. J Gerontol A: Biol Sci Med Sci 2011, 66:312-319.
28. Frenck R.W., Blackburn E.H., Shannon K.M. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci USA 1998, 95:5607-5610.
29. Bekaert S., De Meyer T., Rietzschel E.R., et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 2007, 6:639-647.
30. Demissie S., Levy D., Benjamin E.J., et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 2006, 5:325-330.
31. Nawrot T.S., Staessen J.A., Holvoet P., et al. Telomere length and its associations with oxidized-LDL, carotid artery distensibility and smoking. Front Biosci (Elite Ed) 2010, 2:1164-1168.
32. Sampson M.J., Winterbone M.S., Hughes J.C., et al. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 2006, 29:283-289.
33. Lavezzi A.M., Milei J., Grana D.R., et al. Expression of c-fos, p53 and PCNA in the unstable atherosclerotic carotid plaque. Int J Cardiol 2003, 92:59-63.
34. Wilson W.R., Herbert K.E., Mistry Y., et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 2008, 29:2689-2694.